MedTrace Logo

A Study to Evaluate the Safety of THR-687 in Subjects With Diabetic Macular Edema (DME)

NCT03666923 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2020-01-22

No results posted yet for this study

Summary

This study is conducted to evaluate the safety of a single intravitreal injection of THR-687.

Conditions

Interventions

DRUG

THR-687 dose level 1

single intravitreal injection of THR-687 dose level 1

DRUG

THR-687 dose level 2

single intravitreal injection of THR-687 dose level 2

DRUG

THR-687 dose level 3

single intravitreal injection of THR-687 dose level 3

Sponsors & Collaborators

  • ThromboGenics

    lead INDUSTRY

Principal Investigators

  • Clinical Department · ThromboGenics Inc. A subsidiary of Oxurion NV.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-17
Primary Completion
2019-11-20
Completion
2019-11-20
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03666923 on ClinicalTrials.gov